Home » Stocks » AZN

AstraZeneca plc (AZN)

Stock Price: $48.06 USD 0.83 (1.76%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Pre-market: $47.43 -0.63 (-1.31%) Mar 8, 5:05 AM
Market Cap 125.07B
Revenue (ttm) 26.62B
Net Income (ttm) 3.14B
Shares Out 1.31B
EPS (ttm) 1.22
PE Ratio 39.46
Forward PE 19.34
Dividend $2.80
Dividend Yield 5.83%
Trading Day March 5
Last Price $48.06
Previous Close $47.23
Change ($) 0.83
Change (%) 1.76%
Day's Open 47.55
Day's Range 47.15 - 48.12
Day's Volume 11,023,146
52-Week Range 35.18 - 63.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Newsfile Corp - 11 hours ago

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AstraZeneca plc ("AstraZeneca" or the "Company") (NASDAQ: AZN)...

Newsfile Corp - 1 day ago

New York, New York--(Newsfile Corp. - March 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

Newsfile Corp - 1 day ago

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--...

The Motley Fool - 1 day ago

Europe is already vaccinating with AstraZeneca's product.

Newsfile Corp - 2 days ago

Boston, Massachusetts--(Newsfile Corp. - March 5, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of AstraZeneca PLC (NASDAQ: AZN). Th...

Benzinga - 2 days ago

Preliminary data from a study conducted at the University of Oxford suggests that AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is effective against the P1 or Brazilian variant, reports Reu...

Investors Business Daily - 2 days ago

The AstraZeneca and University of Oxford coronavirus vaccine is effective against the Brazil variant, according to a report. But AstraZeneca stock remained muted Friday.

Benzinga - 2 days ago

Europe's COVID-19 vaccine rollout has come under the spotlight again after the Italian government blocked a shipment of Oxford-AstraZeneca plc (NASDAQ: AZN) shots to Australia, reports CNBC. T...

Newsfile Corp - 3 days ago

New York, New York--(Newsfile Corp. - March 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

Newsfile Corp - 3 days ago

San Francisco, California--(Newsfile Corp. - March 4, 2021) - Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action has been f...

CNBC - 3 days ago

The European Commission, the institution leading the purchase agreements, has been blamed for not securing enough vaccines.

GlobeNewsWire - 3 days ago

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 20...

Newsfile Corp - 4 days ago

New York, New York--(Newsfile Corp. - March 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Astrazeneca Plc (NYSE: AZN) allegi...

GlobeNewsWire - 4 days ago

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 ...

CNBC Television - 4 days ago

AstraZeneca's Dobber on ramping up Covid vaccine production

CNBC's Meg Tirrell talks with AstraZeneca's president of North America Ruud Dobber about how the company is ramping up its global vaccine rollout through Covax and U.S. phase-three vaccine stu...

Newsfile Corp - 4 days ago

New York, New York--(Newsfile Corp. - March 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

InvestorPlace - 4 days ago

Stocks that are worth considering for retirement investors. Low beta stocks with strong fundamentals and a healthy dividend yield.

Other stocks mentioned: COST, JNJ, LMT, PEP, PG, WMT
New York Post - 4 days ago

Pharma giant AstraZeneca sold its stake in Moderna for more than $1 billion last year as the upstart biotech firm's COVID-19 vaccine thrust it into the spotlight. AstraZeneca quietly revealed ...

Other stocks mentioned: MRNA
Skynews - 4 days ago

The Pfizer-BioNTech and Oxford-AstraZeneca coronavirus vaccines are both highly effective at preventing over-80s from being admitted to hospital, according to a new study.

Other stocks mentioned: PFE
The Motley Fool - 4 days ago

Don't be too quick to pull the trigger.

Other stocks mentioned: MRNA
Proactive Investors - 5 days ago

AstraZeneca plc (LON:AZN) said that the US District Court for the Northern District of West Virginia has decided in its favour in litigation against Mylan and Kindeva. The court determined tha...

Forbes - 5 days ago

The chief of the country's public health body urged calm and said that no deaths have yet been confirmed to have a direct link to the vaccine.

CNBC - 5 days ago

European officials are coming under increasing pressure to reverse restrictions on who can receive the AstraZeneca Covid vaccine.

Benzinga - 5 days ago

A recent study revealed that one dose of either Pfizer Inc (NYSE: PFE)/BioNtech SE (NASDAQ: BNTX) or Oxford-AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine is more than 80% effective in reducin...

Other stocks mentioned: BNTX, PFE
Newsfile Corp - 6 days ago

New York, New York--(Newsfile Corp. - March 1, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securit...

GlobeNewsWire - 6 days ago

SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action has been filed and cer...

GlobeNewsWire - 6 days ago

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AstraZeneca PLC (NASDAQ: AZN...

Proactive Investors - 6 days ago

AstraZeneca plc (LON:AZN) has reportedly cashed in US$1.2bn after selling its 7.7% stake in COVID-19 vaccine maker Moderna, Inc. (NASDAQ:MRNA). The FTSE 100 pharma giant will use the proceeds ...

Other stocks mentioned: MRNA
Benzinga - 6 days ago

AstraZeneca Plc (NASDAQ: AZN) has announced a deal with Shanghai Junshi Biosciences Co Ltd to market Junshi's cancer drug. Under the agreement, AstraZeneca will be granted the right to market ...

Benzinga - 1 week ago

British-based drugmaker AstraZeneca plc (NASDAQ: AZN) has sold its 7.7% stake in Moderna Inc. (NASDAQ: MRNA) for more than $1 billion, the Times reported Sunday. What Happened: AstraZeneca dis...

Other stocks mentioned: MRNA
Reuters - 1 week ago

AstraZeneca Plc has sold its stake in Moderna Inc for more than $1 billion after the American biotechnology company's shares soared on the back of its coronavirus vaccine breakthrough, The Tim...

Other stocks mentioned: MRNA
PRNewsWire - 1 week ago

NEW YORK, Feb. 28, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and N...

Newsfile Corp - 1 week ago

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--...

The Motley Fool - 1 week ago

Conditions are ripe for a major stock market rally to take shape under the new administration.

Other stocks mentioned: AMZN, PANW, PINS, USB
Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 26, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired sec...

Benzinga - 1 week ago

AstraZeneca Plc (NASDAQ: AZN) and its partner Amgen Inc (NASDAQ: AMGN) have announced positive results from NAVIGATOR Phase 3 trial evaluating tezepelumab in severe asthma. Results were presen...

Other stocks mentioned: AMGN
PRNewsWire - 1 week ago

LOS ANGELES, Feb. 26, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZen...

Investors Business Daily - 1 week ago

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: BNTX, GILD, GSK, ILMN, JNJ, LLY, MRNA, NVAX, PACB, PFE, REGN, TMO, VIR
Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 25, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Astrazeneca Plc (NYSE: AZN) al...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...

GlobeNewsWire - 1 week ago

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

Other stocks mentioned: BTBT, CLSK, JFU
Business Wire - 1 week ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZ...

Business Wire - 1 week ago

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2...

Newsfile Corp - 1 week ago

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--...

Benzinga - 1 week ago

AstraZeneca plc (NASDAQ: AZN) announced Monday a setback related to its key immuno-oncology therapy Imfinzi. What Happened: The U.K. drugmaker said it is voluntarily withdrawing Imfinzi from t...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AstraZeneca plc (NASDAQ: AZN) ("AstraZeneca" or the "Compa...

GlobeNewsWire - 1 week ago

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 202...

Proactive Investors - 2 weeks ago

AstraZeneca PLC (LON:AZN) announced it has voluntarily withdrawn the use of Imfinzi in patients with locally advanced or metastatic bladder cancer in the US. The decision was made in consultat...

Forbes - 2 weeks ago

European healthcare workers are asking to receive other vaccine doses due to AstraZeneca's lower efficacy, and reports of negative side effects.

About AZN

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbico... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
May 12, 1993
CEO
Pascal Soriot
Employees
76,100
Stock Exchange
NASDAQ
Ticker Symbol
AZN
Full Company Profile

Financial Performance

In 2020, AstraZeneca's revenue was $26.62 billion, an increase of 9.16% compared to the previous year's $24.38 billion. Earnings were $3.14 billion, an increase of 156.23%.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for AstraZeneca stock is "Buy." The 12-month stock price forecast is 62.35, which is an increase of 29.73% from the latest price.

Price Target
$62.35
(29.73% upside)
Analyst Consensus: Buy